Exelixis garners $71M in public offering
Exelixis has rounded up slightly more than $71 million on the close of its public offering. Just days before the offering Exelixis reported encouraging interim data from an ongoing Phase II trial evaluating XL647 as first-line therapy for patients with non-small cell lung cancer, with 60 percent of evaluable patients experiencing clinical benefit as their best response.
- see this release on the offering
Related Articles:
Cancer therapy gets accelerated review at Exelixis. Report
Adverse events force delay in Exelixis trial. Report
Exelixis to collaborate with Genentech. Report
Exelixis signs $157M deal to license hormone receptor. Report
Be the first to comment
More stories about public offering XL647 Genentech adverse events Phase II Exelixis Cancer lung cancer
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
